SEEL Stock Price, Seelos Therapeutics Inc Quote, Chart

Market Summary

USD0.46-0.01

Market Closed

-2.13%

SEEL Stock Price

View Fullscreen

SEEL RSI Chart

SEEL Valuation

Market Cap

6.3M

Price/Earnings (Trailing)

-0.35

Price/Sales (Trailing)

2.86

EV/EBITDA

-4.81

Price/Free Cashflow

-0.26

SEEL Price/Sales (Trailing)

SEEL Profitability

EBT Margin

-1575.09%

Return on Equity

53.37%

Return on Assets

-330.1%

Free Cashflow Yield

-379.97%

SEEL Fundamentals

SEEL Revenue

Revenue (TTM)

2.2M

Rev. Growth (Yr)

1.5K%

Rev. Growth (Qtr)

60.84%

SEEL Earnings

Earnings (TTM)

-17.9M

Earnings Growth (Yr)

-36.41%

Earnings Growth (Qtr)

-342.43%

Breaking Down SEEL Revenue

Last 7 days

-13.2%

Last 30 days

-57.0%

Last 90 days

-67.4%

Trailing 12 Months

-43.2%

How does SEEL drawdown profile look like?

SEEL Financial Health

Current Ratio

0.14

Debt/Equity

2e-5

Debt/Cashflow

-8.8K

SEEL Investor Care

Shares Dilution (1Y)

279.63%

Diluted EPS (TTM)

-10.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	910.0K	1.2M	1.6M	2.2M
2022	120.0K	0	127.0K	128.0K
2021	37.0K	59.0K	94.0K	113.0K
2020	392.0K	409.0K	38.0K	45.0K
2019	4.4M	3.1M	1.7M	375.0K
2016	5.0M	5.0M	8.0M	5.8M
2015	9.7M	4.7M	4.1M	4.8M
2014	0	7.0M	7.7M	9.6M
2013	8.2M	9.4M	4.5M	2.5M
2012	4.7M	5.8M	6.9M	7.9M
2011	5.2M	5.3M	5.0M	3.6M
2010	0	3.6M	4.3M	5.0M
2009	0	0	0	3.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Seelos Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 29, 2024	golembiewski michael joseph	acquired	457	1.097	417	chief financial officer
Dec 01, 2023	mehra raj	bought	99,999	1.32	75,757	see remarks
Nov 30, 2023	golembiewski michael joseph	bought	100,222	1.2075	83,000	chief financial officer
Aug 31, 2023	golembiewski michael joseph	acquired	7,725	0.618	12,500	chief financial officer
Feb 28, 2023	golembiewski michael joseph	acquired	8,400	0.672	12,500	chief financial officer
Jun 01, 2022	o'connor daniel j.	bought	9,788	0.6118	16,000	-
May 26, 2022	dalesandro margaret	bought	20,965	0.599	35,000	-
Mar 31, 2022	mehra raj	bought	56,840	0.8526	66,667	see remarks
Feb 28, 2022	golembiewski michael joseph	acquired	11,262	0.901	12,500	chief financial officer
Feb 13, 2020	mehra raj	bought	99,999	0.75	133,333	see remarks

Which funds bought or sold SEEL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 28, 2024	Newbridge Financial Services Group, Inc.	new	-	277	277	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	sold off	-100	-1,104	-	-%
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-58.00	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	16.00	16.00	-%
Mar 11, 2024	VANGUARD GROUP INC	new	-	394,590	394,590	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-951,782	-	-%
Feb 28, 2024	EP Wealth Advisors, LLC	sold off	-100	-1,840	-	-%
Feb 15, 2024	MERCER GLOBAL ADVISORS INC /ADV	sold off	-100	-22,000	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	sold off	-100	-7,995	-	-%
Feb 15, 2024	State of Wyoming	sold off	-100	-7,366	-	-%

Are Funds Buying or Selling SEEL?

Are funds buying SEEL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SEEL

No. of Funds

Unveiling Seelos Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 06, 2024	lind global fund ii lp	9.9%	1,410,800	SC 13G
Feb 09, 2023	vanguard group inc	4.68%	5,016,741	SC 13G/A
Jul 08, 2022	blackrock inc.	1.7%	1,779,835	SC 13G
Feb 04, 2022	blackrock inc.	6.4%	6,563,054	SC 13G
Feb 10, 2021	vanguard group inc	5.24%	2,799,854	SC 13G
Jan 15, 2021	ligand pharmaceuticals inc	4.1%	2,224,000	SC 13G/A
Jan 11, 2021	phoenixus ag	0%	0	SC 13G/A
Feb 14, 2020	altium capital management lp	0.00%	0	SC 13G/A
Feb 14, 2020	armistice capital, llc	0%	0	SC 13G/A
Feb 12, 2020	ligand pharmaceuticals inc	8.1%	2,224,000	SC 13G/A

Recent SEC filings of Seelos Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Mar 28, 2024	8-K	Current Report
Mar 19, 2024	8-K	Current Report
Mar 15, 2024	EFFECT	EFFECT
Mar 15, 2024	424B3	Prospectus Filed
Mar 12, 2024	CORRESP	CORRESP
Mar 07, 2024	S-8	Employee Benefits Plan
Mar 06, 2024	CORRESP	CORRESP
Mar 06, 2024	10-K	Annual Report
Mar 06, 2024	S-1/A	Initial Public Offering
Mar 01, 2024	4	Insider Trading

Peers (Alternatives to Seelos Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.2B	6.8B	-1.24%	-34.47%	-8.53	5.87	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.7B	1.8B	0.05%	-28.38%	-42.48	10.23	76.23%	61.08%
BMRN	17.4B	2.4B	8.82%	-6.19%	103.82	7.19	15.42%	18.43%
INCY	12.1B	3.7B	-8.57%	-28.49%	20.24	3.27	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.73%	-34.59%	-11.81	15.74	425.83%	18.94%
BBIO	4.7B	-	-4.69%	71.46%	-7.23	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-0.99%	6.40%	-13.71	12.12	440.80%	-27.84%
ARWR	3.1B	240.7M	-13.54%	-18.95%	-10.32	12.72	-1.03%	-92.09%
ACAD	2.8B	726.4M	-12.42%	-7.51%	-46.06	3.89	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-15.36%	25.1	4.5	85.90%	-14.05%
NVAX	599.0M	983.7M	-18.48%	-55.04%	-1.1	0.61	-50.36%	17.16%
CRBP	428.3M	881.7K	-13.30%	407.71%	-9.6	466.16	-77.61%	-5.33%
INO	257.8M	4.9M	-1.96%	-2.22%	-1.91	52.97	-54.97%	51.72%
IBIO	7.2M	2.1M	77.59%	88.99%	-0.26	2.14	-13.45%	66.37%

Seelos Therapeutics Inc News

Latest updates

Seelos Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2016Q4	2016Q3
Revenue	60.8%	653	406	336	808	40.00	36.00	26.00	26.00	39.00	29.00	19.00	7.00	4.00	7.00	27.00	-	375	369	362	356	4,317
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	282	826
Operating Expenses	-33.4%	8,664	13,009	11,289	9,740	18,257	17,410	14,010	27,374	10,910	6,773	16,612	5,845	4,085	3,320	5,509	10,330	4,056	3,394	12,342	-	-
S&GA Expenses	-8.1%	2,746	2,987	2,780	4,072	2,752	2,660	4,001	7,828	2,227	2,465	2,500	2,013	2,070	1,876	1,816	1,132	1,415	1,690	3,322	-	-
R&D Expenses	-40.9%	5,918	10,022	8,509	5,668	15,505	14,750	10,009	-	8,683	4,308	14,112	3,832	2,015	1,444	3,693	-6,303	2,641	100	3,500	-	-
EBITDA Margin	100.0%	-	-15.69*	-20.48*	-37.27*	-206.52*	-209.95*	-212.07*	-207.12*	-242.28*	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-54.8%	19.00	42.00	7.00	7.00	-	2.00	7.00	5.00	20.00	583	990	151	6.00	3.00	4.00	13.00	5.00	6.00	5.00	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.00	1.00
EBT Margin	100.0%	-	-15.75*	-20.53*	-37.35*	-206.98*	-210.45*	-217.77*	-221.63*	-260.87*	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-342.4%	-25,450	10,498	10,498	-13,431	-18,657	-19,604	-14,001	-27,259	-10,815	-8,858	-19,116	-6,450	-4,090	-3,729	-4,832	-10,659	-3,221	-1,863	-35,512	-	-
Net Income Margin	-16.4%	-8.12*	-6.98*	-33.77*	-108.82*	-607.72*	-690.22*	-529.85*	-584.50*	-471.24*	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	66.8%	-1,911	-5,749	-5,904	-10,348	-13,090	-11,074	-17,045	-18,339	-10,510	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-12.9%	5.00	6.00	12.00	24.00	23.00	41.00	53.00	71.00	84.00	81.00	90.00	41.00	17.00	10.00	8.00	14.00	11.00	16.00	10.00	12.00	9.00
Current Assets	-12.7%	5.00	6.00	12.00	24.00	23.00	41.00	53.00	71.00	83.00	81.00	90.00	41.00	17.00	10.00	8.00	14.00	11.00	16.00	10.00	12.00	0.00
Cash Equivalents	15.9%	3.00	3.00	6.00	14.00	16.00	31.00	41.00	62.00	79.00	77.00	87.00	39.00	16.00	8.00	6.00	13.00	10.00	15.00	10.00	11.00	0.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00
Liabilities	6.3%	39.00	37.00	59.00	44.00	33.00	33.00	26.00	25.00	26.00	8.00	8.00	17.00	15.00	3.00	4.00	7.00	11.00	6.00	5.00	9.00	5.00
Current Liabilities	10.2%	39.00	35.00	56.00	39.00	25.00	22.00	15.00	10.00	8.00	8.00	8.00	13.00	7.00	3.00	4.00	7.00	11.00	6.00	-	-	5.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	0.00	3.00	7.00	-	-	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	0.00	2.00	2.00	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	0.00	3.00	7.00	-	-	-	-	-	-	-	-
Shareholder's Equity	-Infinity%	-33.51	-	-	-	-10.61	8.00	26.00	46.00	57.00	73.00	83.00	25.00	3.00	7.00	4.00	7.00	-	10.00	5.00	3.00	3.00
Retained Earnings	-2.2%	-252	-247	-257	-228	-214	196	176	155	-141	-113	-103	-94.28	75.00	-68.71	-64.62	-60.89	-56.06	-45.40	-42.18	-40.32	-4.81
Additional Paid-In Capital	1.2%	219	217	210	207	204	204	203	201	198	187	186	119	78.00	75.00	68.00	68.00	56.00	56.00	47.00	43.00	0.00
Shares Outstanding	84.2%	10.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	2.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	70.00	-	-	-	-	-	262	-	-	-	42.00	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	66.8%	-1,911	-5,749	-5,904	-10,348	-13,090	-11,074	-20,395	-17,045	-18,339	-10,510	-8,894	-11,252	-3,329	-4,180	-6,981	-6,423	-5,118	-2,910	-3,337	-7,940	-397
Share Based Compensation	-1.0%	964	974	988	1,062	-1,934	973	961	2,232	4,900	857	1,037	705	697	695	341	311	4,585	133	144	38.00	-1.00
Cashflow From Financing	-6.7%	2,323	2,490	-2,312	8,874	-1,888	334	-126	83.00	20,240	143	57,407	34,277	10,937	6,380	147	8,850	64.00	8,497	1,773	19,190	100
Buy Backs	-	-	-	-	1,195	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

SEEL Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue
Total revenue	$ 2,203
Revenue, Product and Service [Extensible Enumeration]	us-gaap:GrantMember	us-gaap:GrantMember
Operating expense
Research and development	$ 30,117	$ 58,620
General and administrative	12,585	12,296
Total operating expense	42,702	70,916
Loss from operations	(40,499)	(70,916)
Other income (expense)
Interest income	198	121
Interest expense	(75)	(14)
Change in fair value of convertible notes	(2,049)	(3,017)
Loss on extinguishment of debt	(9,151)
Loss on issuance of common stock and warrants	(4,301)
Change in fair value of warrant liabilities	17,995	292
Total other income (expense)	2,617	(2,618)
Net loss and comprehensive loss	$ (37,882)	$ (73,534)
Total loss per share basic (note 1)	$ (7.73)	$ (20.74)
Total loss per share-diluted (note 1)	$ (7.73)	$ (20.74)
Weighted-average common shares outstanding used for basic (note 1)	4,900,222	3,545,691
Weighted-average common shares outstanding used for diluted (note 1)	4,900,222	3,545,691

SEEL Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash	$ 2,996	$ 15,533
Grant receivable	763
Prepaid expenses and other current assets	1,644	7,141
Total current assets	5,403	22,674
Operating lease right-of-use asset	15	72
Total assets	5,418	22,746
Current liabilities
Accounts payable	16,403	3,626
Accrued expenses	2,516	7,282
Licenses payable		2,195
Short-term portion of convertible notes payable, at fair value	14,213	11,865
Warrant liabilities, at fair value	5,781	132
Operating lease liability	15	58
Total current liabilities	38,928	25,158
Convertible notes payable, at fair value		8,184
Operating lease liability, long-term		15
Total liabilities	38,928	33,357
Commitments and contingencies (note 13)
Stockholders' equity (deficit)
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of December 31, 2023 and December 31, 2022
Common stock, $0.001 par value, 16,000,000 and 8,000,000 shares authorized, 9,794,594 and 3,572,417 issued and outstanding as of December 31, 2023 and December 31, 2022, respectively (note 1)	10	4
Additional paid-in-capital	219,106	204,129
Accumulated deficit	(252,626)	(214,744)
Total stockholders' equity (deficit)	(33,510)	(10,611)
Total liabilities and stockholders' equity (deficit)	$ 5,418	$ 22,746

About Seelos Therapeutics Inc

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.

CEO	Dr. Raj Mehra J.D., Ph.D.
WEBSITE	https://seelostherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	16

Seelos Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Seelos Therapeutics Inc? What does SEEL stand for in stocks?

SEEL is the stock ticker symbol of Seelos Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Seelos Therapeutics Inc (SEEL)?

As of Fri Apr 12 2024, market cap of Seelos Therapeutics Inc is 6.29 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SEEL stock?

You can check SEEL's fair value in chart for subscribers.

What is the fair value of SEEL stock?

You can check SEEL's fair value in chart for subscribers. The fair value of Seelos Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Seelos Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SEEL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Seelos Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SEEL is over valued or under valued. Whether Seelos Therapeutics Inc is cheap or expensive depends on the assumptions which impact Seelos Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SEEL.

What is Seelos Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, SEEL's PE ratio (Price to Earnings) is -0.35 and Price to Sales (PS) ratio is 2.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SEEL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Seelos Therapeutics Inc's stock?

In the past 10 years, Seelos Therapeutics Inc has provided -0.512 (multiply by 100 for percentage) rate of return.